|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Current assets: | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Marketable securities | |||||||||||||||
| Assets held for sale | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Receivables and other current assets | |||||||||||||||
| Total current assets | |||||||||||||||
| Property, plant and equipment, net | |||||||||||||||
| Marketable securities | |||||||||||||||
| Intangible assets, net | |||||||||||||||
| Goodwill | |||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||
| Restricted investments and other non-current assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities and Stockholders’ Equity | |||||||||||||||
| Current liabilities: | |||||||||||||||
| Accounts payable | |||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||
| Operating lease liability, current portion | |||||||||||||||
| Deferred revenue, current portion | |||||||||||||||
| Collaboration research advancement, current portion | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Deferred revenue, net of current portion | |||||||||||||||
| Collaboration research advancement, net of current portion | |||||||||||||||
| Operating lease liability, net of current portion | |||||||||||||||
| Other non-current liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Stockholders’ equity: | |||||||||||||||
| Preferred stock, $0.0001 par value; 10,000 shares authorized, 0 shares issued and outstanding at March 31, 2025 and December 31, 2024 | |||||||||||||||
| Common stock, $0.0001 par value; 200,000 shares authorized, 52,465 and 51,589 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated other comprehensive income | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Total stockholders’ equity | |||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||
| Common stock, shares authorized (in shares) | |||||||||||||||
Loading...
